Abstract
Biological samples are often frozen and stored for years and/or thawed multiple times, thus assessing their stability on long-term storage and repeated freeze–thaw cycles is crucial. The study aims were to assess:—the long-term stability of two major enzymatic and non-enzymatic metabolites of arachidonic acid, i.e. urinary 11-dehydro-thromboxane-(Tx) B2, 8-iso-prostaglandin (PG)F2α, and creatinine in frozen urine samples;—the effect of multiple freeze–thaw cycles. Seven-hundred and three urine samples measured in previously-published studies, stored at −40 °C, and measured for a second time for 11-dehydro-TxB2 (n = 677) and/or 8-iso-PGF2α (n = 114) and/or creatinine (n = 610) were stable over 10 years and the 2 measurements were highly correlated (all rho = 0.99, P < 0.0001). Urine samples underwent 10 sequential freeze–thaw cycles, with and without the antioxidant 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (10 mM); urinary 11-dehydro-TxB2 and creatinine were stable across all cycles (11-dehydro-TxB2: 100.4 ± 21%; creatinine: 101 ± 7% of baseline at cycle ten; n = 17), while 8-iso-PGF2α significantly increased by cycle 6 (151 ± 22% of baseline at cycle ten, n = 17, P < 0.05) together with hydrogen peroxide only in the absence of antioxidant. Arachidonic acid metabolites and creatinine appear stable in human urines stored at −40 °C over 10 years. Multiple freeze–thaw cycles increase urinary 8-iso-PGF2α in urine samples without antioxidants. These data are relevant for studies using urine samples stored over long-term and/or undergoing multiple freezing–thawing.
Subject terms: Biomarkers, Medical research
Urine samples donated alongside large clinical cohorts are usually frozen and stored for years or even decades after collection. Therefore, assessing the long-term stability of specific metabolites is crucial for reliable measurements over time and data interpretation. Arachidonic acid (AA) is a polyunsaturated fatty acid, released from membrane phospholipids by phospholipase A2 (PLA2) and in humans undergoes enzymatic and non-enzymatic biotransformation1,2. In activated platelets, AA is enzymatically transformed mainly via cyclooxygenase (COX) and thromboxane (Tx) synthase into TxA2, that is short-lived, and non-enzymatically hydrated into the inactive, stable TXB22. In the human liver, TxB2 is biotransformed by different enzymatic pathways into several stable final metabolites, excreted in urine (Fig. 1)3, with 11-dehydro-TxB2 being amongst the most abundant and largely generated by activated platelets4–6. Consistent with its origin, urinary 11-dehydro-TxB2 is enhanced in conditions at high atherothrombotic risk, e.g. diabetes mellitus, hypertension, acute coronary syndromes, and stroke7,8. Moreover, 11-dehydro-TxB2 has been shown in large prospective cohorts to be a biomarker predicting major future cardiovascular events including mortality, as well as non-cardiovascular mortality and cancer over 5–12 years follow-up7–10.
Figure 1.
Metabolism of thromboxane A2/B2 and isoprostanes in humans. The figure shows the enzymatic and non-enzymatic metabolism of arachidonic acid toward thromboxane (Tx)A2/B2 and isoprostanes; approximately 70-80% of TxA2 generated daily in humans is released by platelets and rapidly hydrolysed to TxB23 which is then enzymatically biotransformed in the liver into 20 stable metabolites, the main being 11-dehydro-TxB2 and 2,3-dinor-TxB2 excreted by the kidney. The non-enzymatic metabolism of arachidonic acid generates 8-iso-prostaglandin (PG)F2α which is excreted unchanged in urine. ALHD: aldehyde dehydrogenase; PLA2: phospholipase A2; TPs: thromboxane A2 receptors.
By means of reactive oxygen species, AA is non-enzymatically oxidized into F2 isoprostanes that are excreted by the kidney (Fig. 1)11. In particular, the 8-iso-prostaglandin (PG)F2α is the most abundant in human urine12, reflecting in vivo lipid peroxidation2,13. Consistently, urinary 8-iso-PGF2α is increased in conditions at high cardiovascular risk as well as high oxidative stress such as cigarette smoking, diabetes mellitus hypercholesterolemia, and obesity14. In addition, urinary 8-iso-PGF2α has been reported as an independent biomarker of future cardiovascular events and mortality15,16. In the large longitudinal Framingham cohort, urinary 8-iso-PGF2α and 11-dehydro-TxB2 were significantly correlated9.
Thus, urinary 11-dehydro-TxB2 and 8-iso-PGF2α metabolites have been measured in large longitudinal studies8,9,17, possibly years after collection, however their long-term stability has never been assessed while is rather relevant. Both metabolites contain cycloalkanes, double bonds, as well as oxygen and hydroxyl groups (Fig. 1)18, which may affect their long-term stability and antigenic properties in immunometric measurements.
Thus, the aims of this study were: (i) to investigate the effect of long-term storage on the concentration of 11-dehydro-TXB2, 8-iso-PGF2α and creatinine (as a control molecule), in urine and chromatographic extracts of urine, all stored at −40 °C, and (ii) to assess the effect of repeated freeze–thaw cycles in urine samples and in chromatographic extracts.
Materials and methods
Study samples
Urine samples from 703 subjects (51 healthy individuals19,20, 61 patients with diabetes mellitus20,21[Petrucci et al. accepted for publication], 242 patients with hematologic22,23 and 349 with solid cancers10 were assayed a first time in previously-published studies10,19–23[Petrucci et al. accepted for publication]. In the original protocols, all urine samples were collected from study participants and frozen within 2–3 h from collection at −40 °C, under controlled temperature (PDF 440W, EVERmed, Medical Refrigeration; Motteggiana, MN and KBPF600 PP, KW Apparecchi Scientifici srl, Monteriggioni, SI, all in Italy) until first measurement. After the first measurement samples were stored at −40 °C, under controlled temperature until the present study.
For this study, urine samples were selected if: 1- there was a first measure of 11-dehydro-TxB2, creatinine and/or 8-iso-PGF2α, depending on the original protocol; 2- the remaining volume was sufficient for a second extraction and/or creatinine measure, i.e. ≥ 2 mL;—they were correctly stored under controlled temperature of -40 °C over the indicated time interval between 1 week and 10 years.
Eleven-dehydro-TxB2 and 8-iso-PGF2α measurements
Thawed samples were centrifuged at 671 g for 5 min (Centrifuge-5702, Eppendorf, Milan, Italy), 1 mL of the supernatant underwent chromatographic extraction, as previously described24. Briefly, 2000 cpm of 3H-PGE2 (3.70–6.86 TBq/mmol, Perkin Elmer, Boston, MA, USA) was added to 1 mL urine and loaded into a 1 mL/50 mg C18 column (Bakerbond™-SPE, J.T. Baker, Gliwice, Poland) and eluted with 2.5 mL isooctane/ethyl acetate (1:1, vol/vol). The first eluate was loaded into a 1 mL/100 mg SiOH column (Bakerbond™-SPE) and eluted with 2 mL ethyl acetate/methanol (60:40, vol/vol), samples were then dried and resuspended in 1 mL PBS/0.1% BSA buffer (pH 7.4) for immunoassay and assessment of recovery calculated on the 3H-PGE2 counting. The variability of the urine extraction method calculated on repeated extractions of the same samples was 12% over the entire study duration (n = 24 samples extracted multiple times).
For 11-dehydro-TxB2, 677 suitable urine samples, extracted as described above, were assayed by a standard enzyme-linked immunosorbent assay (ELISA) as previously published25, using a specific rabbit polyclonal antiserum26 with a detection range from 3.9 to 500 pg/mL and a sensitivity calculated as 80% B/B0 (i.e. the relative maximum binding in a sample to maximum binding capacity) of 10 pg/mL. The inter-assay variability, calculated as the coefficient of variation of repeated measurement of a commercial standard (11-dehydro-TxB2 ELISA Standard, Cayman Chemical, Ann Arbor, MI, USA), was 9% (n = 1344 determinations) over the entire study duration. The accuracy of the ELISA was assessed using a commercial standard of 1.5 ng/mL (Cayman Chemicals) that measured 1.57 ± 0.14 ng/mL (n = 20 measurements). The cross-reactivity of the anti-11-dehydro TxB2 antiserum against other prostanoids that can be measured in urine, namely PGE2 2,3-dinor TXB2, TXB2, 6-keto PGF1α, and the isoprostane 8-iso-PGF2α was < 0.05%, and against PGD2 was 0.3%.
For 8-iso-PGF2α, 114 suitable urine samples were processed and immuno-assayed as previously described25 with a specific rabbit polyclonal antiserum27 with a detection range from 3.9 to 500 pg/mL, the sensitivity of 9 pg/mL and an inter-assay coefficient of variation using a commercial standard (8-isoprostane ELISA Standard, Cayman Chemical) of 7.8% over the entire study duration (n = 194 determinations). The cross-reactivity for the anti-8-iso-PGF2α antiserum against other urinary prostanoids was < 0.5% namely PGE2, 2,3-dinor TXB2, TXB2, 2,3-dinor-6-keto PGF1α was < 0.05%, and against PGD2 and 6-keto PGF2α was 0.16%. The accuracy assessed with a certified commercial standard (Cayman Chemical) of 10 ng/mL measured 11.4 ± 1.3 ng/mL (n = 10 measurements).
The stability of 11-dehydro TxB2 and 8-iso-PGF2α as also assessed in chromatographic extracts stored in PBS at −40 °C between 1 week and 10 years. Extracts were assayed again by ELISA for 11-dehydro TxB2 (n = 748 samples) and/or for 8-iso-PGF2α (n = 212 samples) as described.
Both ELISA methods used in the current study had been previously validated against gas chromatography/mass-spectrometry (GC/MS) and showed a strong correlation between the analysis of identical urine samples for 11-dehydro TxB2 and 8-iso-PGF2α25,27.
Creatinine measurements
For creatinine, 610 urine samples from 53 healthy individuals19,20, 189 patients with diabetes mellitus [Petrucci et al. submitted], 110 patients with hematologic21,22, and 258 with solid cancers10, were assayed for a second time for creatinine using a commercial kit (Creatinine Colorimetric Detection Kit; Enzo Life Sciences, Farmingdale, NY, USA). The inter-assay coefficient of variation using a commercial standard (Creatinine Standard, Cayman Chemical) was 7% over the study duration (n = 523 determinations).
Freeze–thaw experiments
Forty urine samples from 37 volunteers were collected and aliquoted into 1.5 mL samples without antioxidant. One aliquot was immediately processed (baseline sample) and the remaining aliquots that were frozen at −80 °C for 20 min and thawed in water bath at 25 °C for 10 min multiple times. In 24 samples the antioxidant 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (4-hydroxy-TEMPO) (Merck KGaA, Darmstadt, Germany, 10 mM final concentration), was added immediately after collection and samples underwent multiple freeze thaw cycles as already described.
The urinary pH was measured at thawing cycles 2, 4, 8 and 10 using a pH tester (pH510, Eutech Instruments Europe B.V.—Landsmeer, The Netherlands).
To evaluate the oxidative stress we measured hydrogen peroxide (H2O2) levels, an established index of reactive oxygen species generation28,with a commercial kit (Peroxide Assay Kit, Merck KGaA) that measures H2O2 using a chromogenic Fe3+ − xylenol orange reaction based on the Fenton reaction. The colorimetric intensity is proportional to the H2O2 concentration in the sample.
The effect of freeze–thaw cycles was also investigated in the chromatographic extracted samples in PBS, by pooling extracts and making aliquots for multiple freeze–thaw cycles, as described.
Statistical analysis
Since the second measurement was dependent on both the availability of a first measurement performed for a specific protocol as well as on an appropriate remaining sample volume, we did not formulate a specific hypothesis for sample size over time.
Data from the repeated measurements and the freeze–thaw experiments were plotted as % of the first or baseline measurement, respectively, as indicated. Data were expressed median and interquartile ranges. Comparisons were performed by ANOVA for repeated measurements or paired t-test, as appropriate. Correlations were analysed by Pearson or Spearman's rank test according to data distribution. The significance was set at P < 0.05. Analyses were performed using GraphPad Prism 7.04.
All samples were received anonymized in the central laboratory at the Catholic University School of Medicine in Rome (to GP and BR), since were labelled only using alphanumeric codes, according to the original protocols. Each study protocol was approved by the referent Ethics Committee, namely: South Central-Oxford C, UK, ref 14/SC/017110, Rome, Italy, ref P/852/CE/201219, ref. P/464/CE/201020, ref 32(A.1668)/CE/2009, Center of Rome21, ref 28,371/16, ID 128523; Santo Spirito Hospital, Pescara, Italy, ref 204 CE/201022; North West Multi-centre Research Ethics Committee,0.29/12/2003, ref: 03/8/087, sub-study TXM [Petrucci et al. accepted for publication]. All protocols were performed in accordance with the Helsinki declaration29 and written informed consent for study participation and measurements of urinary metabolites was obtained from all study participants.
Results
Eleven-dehydro-TxB2, 8-iso-PGF2α and creatinine in stored samples
Biomarkers in urine samples
Eleven-dehydro-TxB2 levels, expressed as % of the first measurement, were stable in urine samples stored between 1 week and 10 years (n = 677, Fig. 2a). Values of the first and second measurement were similar (750.5 [348.2–11850] and 743.1 [354–11563] pg/mL, median and [interquartile range], respectively) and highly correlated (rho = 0.99, P < 0.0001, n = 677, Fig. 2b). Similarly, 8-iso-PGF2α levels were largely stable between 2 weeks and 10 years (n = 114, Fig. 2c); overall, the second measurements were similar to the first ones (497 [279.6–850] and 507.6 [277.1–807.3] pg/mL, respectively) and highly correlated (rho = 0.99, P < 0.0001, n = 114, Fig. 2d).
Figure 2.
Eleven-dehydro-TxB2, 8-iso-PGF2α, and creatinine in urine samples stored for up to 10 years. Panel (a) shows 11-dehydro-TxB2 (pg/mL) values in urine samples stored from 1 week up to 10 years. Values are represented as % of the first extraction. Panel (b) represents the absolute values of 11-dehydro-TxB2 (pg/mL) on the first versus the second extraction. Dotted line is the correlation. Panel (c) shows 8-iso-PGF2α (pg/mL) values in urine samples stored from 2 weeks up to 10 years. Values are % of the first extraction. Panel (d) represents the absolute values of 8-iso-PGF2α (pg/mL) on the first versus the second extraction. Dotted line is the correlation. Panel (e) shows urinary creatinine values in urine samples stored from 1 week up to 10 years. Values are % of the first creatinine measurement. Panel (f) represents the absolute values of creatinine (mg/mL) on the first versus the second measurement. Dotted line is the correlation. PG: prostaglandin; Tx: thromboxane.
We measured urinary creatinine as a reference molecule and based on the consideration that final 11-dehydro TxB2 and 8-iso-PGF2α concentrations are corrected for creatinine excretion to adjust for kidney function (final values expressed as pg/mg creatinine). Creatinine concentrations were also stable (n = 610, Fig. 2e), reproducible (1.0 [0.55–1.54] and 0.99 [0.54–1.54] mg/mL, first and second measurement, respectively) and highly correlated (rho = 0.99, P < 0.0001, n = 610, Fig. 2f).
Based on volume availability, we measured 11-dehydro TxB2, 8-iso-PGF2α, as well as creatinine in some samples; 11-dehydro-TXB2 values expressed as pg/mg creatinine (n = 143), were also stable over 10-year storage (Fig. 3a), with similar concentrations (394.7 [185.7–1006] and 420 [201.6–1045] pg/mg creatinine, first and second determination, respectively) and highly correlated (rho = 0.99, P < 0.0001, n = 143, Fig. 3b). In 77 urine samples 8-iso-PGF2α concentrations expressed as pg/mg creatinine did not significantly change over 10 years (Fig. 3c) with similar levels (470.2 [218.8–929.7] and 455 [234.5–1032] pg/mg creatinine, in the first and second measurement, respectively) and highly correlated (rho = 0.99, P < 0.0001, Fig. 3d).
Figure 3.
Eleven-dehydro-TxB2 and 8-iso-PGF2α expressed as pg/mg creatinine in urine samples stored for up to 10 years. Panel (a) shows 11-dehydro-TxB2 (pg/mg creatinine) values in urine samples stored from 1 week up to 10 years. Values are % of the first extraction. Panel (b) represents the absolute values of 11-dehydro-TxB2 (pg/mg creatinine) on the first versus the second extraction. Dotted line is the correlation. Panel (c) shows urinary 8-iso-PGF2α (pg/mg creatinine) values in urine samples stored from 2 week up to 10 years. Values are % of the first extraction. Panel (d) represents the absolute values of 8-iso-PGF2α (pg/mg creatinine) on the first versus the second extraction. Dotted line is the correlation. PG: prostaglandin; Tx: thromboxane.
Chromatographic extracted samples from urine
As a control for the medium for the considered metabolites, we also performed immunoassays in chromatographic extracts of urine samples which were eluted and in PBS. In these extracts (n = 748), only the 11-dehydro-TXB2 was stable over time (Fig. 4a) with similar concentrations (543[210–1172] and 552.5[199–1181] mg/mL, first and second determination, respectively), with highly correlated values (rho = 0.99, P < 0.0001, Fig. 4b), while 8-iso-PGF2α in chromatographic frozen extracts (n = 212) showed a significant trend toward a decrease starting approximately from month 4 of storage (Fig. 4c), even though the values of the 2 measurements were still significantly correlated (rho = 0.85, P < 0.0001, n = 212, Fig. 4d).
Figure 4.
Eleven-dehydro-TxB2 and 8-iso-PGF2α levels in chromatographic extracts stored for up to 10 years. Panel (a) shows 11-dehydro-TxB2 (pg/mL) values in chromatographic extracts stored in PBS from 1 week up to 10 years. Values are % of the first measurement. Panel (b) represents 11-dehydro-TxB2 (pg/mL) absolute values on the first versus the second measurement. Dotted line is the correlation. Panel (c) shows 8-iso-PGF2α (pg/mL) repeated values in chromatographic extracts stored in PBS from 2 week up to 10 years. Values are % of the first measurement. Panel (d) represents 8-iso-PGF2α (pg/mL) absolute values on the first versus the second measurement. Dotted line is the correlation. PG: prostaglandin; Tx: thromboxane.
Freeze–thaw cycles
In urine samples without added antioxidant, 11-dehydro-TxB2 and creatinine concentrations were stable over 10 freeze–thaw cycles and were 100.4 ± 21% (n = 17) and 101 ± 7% of baseline (n = 20), respectively at cycle 10 (Fig. 5a and 6a). However, 8-iso-PGF2α concentrations showed a significant increase starting from cycle 6, being 134 ± 9% of baseline at cycle 6 (n = 17, P < 0.001, Fig. 5b). We also measured H2O2 concentration in urine to assess whether oxidation products were increased by multiple freezing and thawing, and observed a parallel, significant 24.4 ± 15-fold increase vs. baseline by cycle 8 (P < 0.0001, Fig. 5c). When the antioxidant was added to urine samples, the urinary 8-iso-PGF2α and H2O2 levels remained stable over the 10 freeze–thaw cycles (Fig. 5b,c).
Figure 5.

Effect of freeze-thawing cycles on 11-dehydro-TxB2, 8-iso-PGF2α and H2O2 in urine samples. Panel (a) shows the effect of up to 10 freeze-thaw cycles on 11-dehydro-TxB2 in urine samples with or without 10 Mm 4-OH-TEMPO. Panel (b) shows the effect of up to 10 freeze-thaw cycles on 8-iso-PGF2α in urine samples with and without 10 mmol 4-OH-TEMPO. Panel (c) shows the effect of up to 10 freeze-thaw cycles on peroxides in urine samples (n = 3) with and without 10 mM 4-OH-TEMPO. Data are expressed as percentage of the corresponding baseline values and are means ± SD. *P < 0.0001 versus baseline. 4-OH-TEMPO: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; PG; prostaglandin; Tx: thromboxane.
Figure 6.

Effect of freeze–thaw cycles on urinary creatinine and on 11-dehydro-TxB2, 8-iso-PGF2α in chromatographic-extracts. Panel (a) shows the effect of 10 freeze-thaw cycles on creatinine in urine samples, each column represents means ± SD of n = 20 measurements. Panel (b) shows the effect of 10 freeze-thaw cycles on 11-dehydro-TxB2 and 8-iso-PGF2α in chromatographic-extracted samples, each column represents means ± standard deviations of n = 10 determinations. Data are expressed as percentage of the corresponding baseline values. All values are not significantly different versus baseline. 4-OH-TEMPO: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; PG; prostaglandin; Tx: thromboxane.
At variance with urine samples, 11-dehydro TxB2 and 8-iso-PGF2α in the chromatographic extracts were stable over the 10 freeze–thaw cycles (Fig. 6b).
The urinary pH values with and without antioxidant were not affected by the 10 freeze–thaw cycles (data not shown).
Discussion
This study investigated for the first time the stability of the 2 major urinary enzymatic and non-enzymatic metabolites of AA, i.e., the 11-dehydro-TxB2 and the 8-iso-PGF2α, respectively, as well as of creatinine as a control molecule, in a large number of urine samples stored at –40º C for several years and in chromatographic urinary extracts, as control for the storage medium for these analytes (urine versus PBS in purified extracts). We also assessed the effect of multiple freeze–thaw cycles on the same metabolites in both urine and extract samples. To the best of our knowledge, this study has the largest sample size and the longest storage interval assessing stability.
In over 700 urine samples, we observed a substantial stability of 11-dehydro-TxB2, 8-iso-PGF2α, and creatinine levels between few weeks and 10 years, with a variability of the repeated values that remained within the coefficient of variation of the methods. We included different type of subjects from different studies, to evaluate whether in protein- and glucose-enriched urine, as in the case of diabetes mellitus, there were differences in the stability of the studied metabolites and creatinine. The stability of 11-dehydro-TxB2 and 8-iso-PGF2α in urine samples stored at −40 °C over 10 years, was observed in all studied groups, i.e. healthy, diabetes mellitus and cancer subjects (Table 1). Previous studies on the 8-iso-PGF2α reported stability in urine stored at −20 °C for up to 6 months30, at −70 °C for a maximum of 2 years (Table 2)31, and a recent study showed that both 11-dehydro-TxB2 and 8-iso-PGF2α are stable in urine samples stored at both −20 and −70 °C over 3 years (Table 2)32. Thus, our data are consistent with and enlarge evidence from previous, smaller studies. Notably, our urine samples were stored at −40 °C for 10 years, which is a condition more feasible and cheaper as compared to lower storage temperatures, e.g. −80 °C, especially in large biobanks.
Table 1.
Concentrations of 11-dehydro-TXB2, 8-iso PGF2α, and creatinine in urine samples stored for up to 10 years, overall and in each subgroup.
| Groups | 11-dehydro-TXB2 (pg/mL) |
8-iso-PGF2α (pg/mL) |
Creatinine (mg/mL) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Time (years) vs % of the 1st extraction (rho) | 1st vs 2nd measurement (rho) |
n | Time (years) vs % of the 1st extraction (rho) | 1st vs 2nd Measurement (rho) |
n | Time (years) vs % of the 1st extraction (rho) | 1st vs 2nd Measurement (rho) |
|
| All samples10,19–22 | 677 |
0.04 P = 0.3 |
0.99 P < 0.0001 |
114 |
0.27 P = 0.04 |
0.99 P < 0.0001 |
610 |
−0.07 P = 0.83 |
0.99 P < 0.0001 |
| Healthy subjects19,20 | 51 |
0.24 P = 0.1 |
0.99 P < 0.0001 |
55 |
0.17 P = 0.2 |
0.99 P < 0.0001 |
53 |
0.09 P = 0.5 |
0.99 P < 0.0001 |
| Diabetic patients20,21 | 35 |
0.11 P = 0.5 |
0.99 P < 0.0001 |
59 |
−0.12 P = 0.4 |
0.99 P < 0.0001 |
189 |
0.02 P = 0.8 |
0.99 P < 0.0001 |
| Cancer patients10,22,23 | 591 |
0.03 P = 0.5 |
0.99 P < 0.0001 |
NA | NA | NA | 368 |
0.12 P = 0.04 |
0.99 P < 0.0001 |
PG; prostaglandin; NA: data not available; TX: thromboxane.
Table 2.
Effect of storage conditions and freeze–thaw cycles on different compounds in urine samples.
| Storage conditions | ||||
|---|---|---|---|---|
| Study (year) | Study design | Storage conditions | Study population | Results |
| Spierto et al.35 | Stability of urinary creatinine under different storage conditions | 30 days at 4, 25, 37, and 55 °C | Healthy individuals (n = 10) | Creatinine levels remained stable at 4, 25, 37 °C, but significantly decreased at 55 °C as compared to the baseline;—42%; P < 0.05 |
| Pagliaccia et al.24 | Stability of 11-dehydro-TxB2, 8-iso-PGF2α and creatinine in urine samples under different storage conditions | 7 days at 4 and 25°C with and without antioxidant (1mM 4-OH-TEMPO) | Healthy individuals (n = 11) and patients with type 2 diabetes mellitus (n = 15) | All urinary analytes remained stable in urine samples |
| Remer et al.37 | Long-term stability of Creatinine, urea, chloride, phosphate, sodium, potassium, calcium, magnesium, citrate, uric acid, iodine, and nitrogen in urine samples from the Dortmund Nutritional and Anthropometric Longitudinally Designed Study | 12–15 years at −22 °C | Healthy children (n = 10) | All urinary analytes were stable over 15 years |
| Holder et al.31 | Stability of 8-iso-PGF2α while developing an analytical method by mass spectrometry | 2 years at −70 °C | 2 urine pools from healthy subjects | 8-iso-PGF2α values were stable over 2 years |
| Sieminska et al.32 | Stability of 11 dehydro-TxB2, 8-iso-PGF2α and other 17 eicosanoids while developing an analytical method by a single extraction 96-well method for LC–MS/MS quantification | 3 years at −20 and −70 °C | 5 urine pools from healthy subjects |
Polar tetranors (tetranor-PGDM, -PGFM, -PGEM and -PGAM) showed a 50% of reduction after 5 months at −20°C, while 11 dehydro-TxB2, 8-iso-PGF2α and other eicosanoids were stable over 3 years at −20°C All urinary analytes were stable over 3 years at −70°C |
| Present study | Stability of 11-dehydro-TxB2, 8-iso-PGF2α and creatinine in frozen urine samples and in chromatographic extracts of urine over a long time interval | To 1 week up to 10 years at −70 °C | Healthy individuals (n = 51), patients with diabetes (n = 61), patients with hematologic (n = 242) and solid cancers (n = 349) |
11-dehydro-TxB2, and creatinine were stable in urine samples and in their chromatographic extracts up to 10 years at −40 °C 8-iso-PGF2α was stable in urine samples up to 10 years at −40 °C, but significantly decreased in chromatographic extracts of urine starting approximately from month 4 of storage; rho = −0.72; P < 0.0001 |
| Freeze–thaw cycles | ||||
| Study (year) | Study design | Cycles and Temperature | Study population | Results |
| Bao et al.41 | Effect of freeze–thaw on albumin and creatinine in urine samples | 5 cycles (freeze: −30 °C, thaw: room temperature) | Patients with chronic kidney disease (n = 53) | Albumin and creatinine remained stable |
| Zhang et al. (2015)42 | Effect of freeze–thaw on total protein, albumin, and calcium in urine samples | 6 cycles (freeze: −20 and −80 °C, thaw: room temperature) | Patients with chronic kidney disease (n = 11) |
All biomarkers freezed at −20 and −80 °C significantly decreased versus baseline: Total protein: - Freeze -20 °C: 2.48 ± 1.51 vs 0.75 ± 0.58 g/L; P < 0.05 - Freeze -80 °C: 2.48 ± 1.51 vs 0.96 ± 1.1 g/L; P < 0.05 Albumin: - Freeze -20 °C: 1.67 ± 1 vs 0.73 ± 0.66 g/L; P < 0.05 - Freeze -80 °C: 1.67 ± 1 vs 0.59 ± 0.39 g/L; P < 0.05 Calcium: - Freeze -20 °C: 1.64 ± 1.52 vs 0.69 ± 0.6 umol/L; P < 0.05 - Freeze -80 °C: 1.64 ± 1.52 vs 0.94 ± 0.92 umol/L; P < 0.05 |
| Holder et al.31 | Effect of freeze–thaw on 8-iso-PGF2α while developing an analytical method by mass spectrometry | 3 cycles (freeze: −70 °C, thaw: room temperature) | 2 urine pools from healthy subjects | 8-iso-PGF2α remained stable |
| Present study | Effect of multiple freeze–thaw on 11-dehydro-TxB2, 8-iso-PGF2α and creatinine in frozen urine samples with and without antioxidant and in chromatographic extracts of urine | 10 cycles (freeze: −80 °C, thaw: in water bath at 25 °C for 10 min) | 40 urine samples with and without antioxidant and 10 chromatographic extracts |
11-dehydro-TxB2 and creatinine remained stable in urine samples with and without antioxidant and in chromatographic extracts of urine 8-iso-PGF2α remained stable in urine samples with antioxidant in chromatographic extracts of urine 8-iso-PGF2α significantly increased versus baseline after cycle 6 in urine samples without antioxidant; P < 0.0001 |
°C: degrees Celsius; PG: prostaglandin; TX: thromboxane.
To compare the stability of these molecules in different suspension media, in addition to the physiological urine milieu, we re-measured the chromatographic extracts from urine, which contain the purified lipid fraction in PBS. The 11-dehydro-TxB2 levels were stable also in PBS milieu, while the 8-iso-PGF2α levels progressively decreased starting from approximately 4 months of storage. This progressive decrease in 8-iso-PGF2α may be related to its chemical structure that includes a cyclopentane33 which is possibly less stable in PBS at pH 7.4 than the oxane ring of 11-dehydro-TxB218,33. Eleven-dehydro-TxB2 has extra chemical resonance forms due to the double-bonded oxygen which may further stabilize the molecule33, while the number and position of the hydroxyl groups in the 8-iso-PGF2α molecule may increase its reactivity and instability34. Since the 8-iso-PGF2α was stable in urine but not in chromatographic extracts, we can hypothesize that the molecule is less stable at higher pH, as for PBS versus urine and/or in solutions containing salts like ethylene-diamine-tetra-acetic acid. Further investigations will be needed to clarify this difference in stability.
Concerning urinary creatinine, previous studies had investigated its stability in different storage conditions and time-intervals, as summarized in Table 2. Creatinine levels were stable in urine samples kept at 37 °C for 30 days, while at > 55 °C creatinine levels decreased (Table 2)35, likely due to temperature-driven degradation36. We had previously studied urine samples kept for 7 days at room temperature and observed stable concentrations over this short time interval as well (Table 2)24. Creatinine was also stable in samples stored at −22 °C over 15 years (Table 2)37, which is consistent with our findings. Notably, we studied urine samples from different conditions (healthy, diabetes mellitus and cancer) and creatinine values were consistently stable in all groups (Table 1).
Since the same urine samples stored in biobanks are usually used multiple times, undergoing multiple freeze–thaw cycles, we investigated the effect freeze–thaw cycles on both urine and extracted samples. Freeze–thaw cycles had been reported to variously affect some urinary metabolomic profiles38, with acylcarnitine and hexose39, acetate, benzoate and succinate significantly increasing while formate and urea decreasing after 8 freeze/thaw cycles40. Urinary albumin appeared stable in urine samples up to 5 freeze–thaw cycles and decreased from cycle 6 (Table 2)41,42. Urinary creatinine was reported stable over 8 cycles40 which is consistent with our data. 8-iso-PGF2α and 11-dehydro-TxB2 have been previously studied in urine and PBS medium after a maximum of 3 freeze‐thaw cycles (Table 2)31,41,43,44. Our data confirm and expand the stability of 11-dehydro-TxB2 and creatinine in urine up to 10 consecutive freeze–thaw cycles, while a significant progressive increase in 8-iso-PGF2α and hydrogen peroxide concentrations were observed starting from 5 to 6 cycle in samples without antioxidant. Approximately 40% of 8-iso-PGF2α has been shown to be excreted in human urine as glucuronide conjugate and increasing pH has been reported to increase glucuronidase hydrolysis and the concentration of un-conjugated F2 isoprostane45. However, our experiments showed no changes in pH in urine samples by freezing and thawing, so it is unlikely that the increase in 8-iso-PGF2α results from release of unconjugated compound. Increased concentration of H2O2 triggered by multiple freezing–thawing may lead to a non-enzymatic oxidation of AA from cell membrane residues or other contaminants in urine. Interestingly, PLA2 has been found in urine of mice46–48, healthy subjects and patients46,48,49 and reported to be activated by freeze–thaw cycles by urinary invertase39. Moreover, freezing–thawing of cells and biological fluids has been reported to increase different reactive oxygen species, mostly H2O2 and superoxide anion50–52. Consistent with this hypothesis, in the chromatographic extracts eluted in clean PBS with no contaminants, freeze–thaw cycles did not affect the 8-iso-PGF2α. Whichever the origin of free AA in urine, our data indicate that it may undergo oxidation into 8-iso-PGF2α as indicated by the increased concentration of H2O2that reflects the oxidation level in the sample28. Consistently, 8-iso-PGF2α was stable when the antioxidant 4-hydroxy-TEMPO was added, which also blocked H2O2 increase.
Our study has some limitations: we did not investigate the stability of those biomarkers in urine samples and chromatographic extracts under different storage temperatures. However, since these metabolites were stable at −40 °C, it can be assumed that −80 °C storage would give similar results, while the stability at −20 °C may be shorter. Previous studies have reported the stability of 8-iso-PGF2α at −70 °C for up to 2 years31. Furthermore, we have not studied the stability of 8-iso-PGF2α during freeze–thaw cycles in urine samples with PLA2 inhibitors, nor measured AA levels in urine samples. Also, in the freeze–thaw experiments small urine aliquots underwent rapid freezing at −80 °C but freezing at −40 °C or higher was not tested.
In conclusion, we showed that urinary 11-dehydro-TxB2, 8-iso-PGF2α and creatinine are stable in urine samples stored for a decade at −40 °C. Urinary 8-iso-PGF2α levels were stable for shorter time in chromatographic extracts and increased by multiple freeze–thaw cycles in urine. These data could inform correlative science projects associated with large clinical datasets analysing samples stored in biobanks for several years and undergoing multiple cycles of freezing and thawing.
Author contributions
G.P., B.R., designed the study. G.P., D.H., performed the experiments; G.P., D.H., and B.R. analysed the data and wrote the original draft. R.L., S.C., A.GM. D.P., A.R., P.R., F.Z., participated in screening and recruiting patients. All Authors (G.P., D.H, R.L., S.C., A.GM. D.P., A.R., P.R., F.Z., discussed the results, commented, and reviewed the manuscript.
Funding
This work was supported by the AsCaP collaboration (C569/A24991#2) and in part by the institutional Linea D1 2021 and Linea D1 2022 Grants to GP and BR.
Data availability
The dataset analyzed in the current study can be acquired from the corresponding author upon motivated request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Patrono C, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 1980;17:317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
- 2.Badimon L, Vilahur G, Rocca B, Patrono C. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc. Res. 2021;117:2001–2015. doi: 10.1093/cvr/cvab003. [DOI] [PubMed] [Google Scholar]
- 3.Roberts LJ, 2nd, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J. Biol. Chem. 1981;256:8384–8393. doi: 10.1016/S0021-9258(19)68855-1. [DOI] [PubMed] [Google Scholar]
- 4.Ciabattoni G, et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim. Biophys. Acta. 1989;992:66–70. doi: 10.1016/0304-4165(89)90051-2. [DOI] [PubMed] [Google Scholar]
- 5.Catella F, Fitzgerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thrombosis Res. 1987;47:647–656. doi: 10.1016/0049-3848(87)90103-4. [DOI] [PubMed] [Google Scholar]
- 6.Patrono C, et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Investig. 1986;77:590–594. doi: 10.1172/JCI112341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Patrono C, Rocca B. Measurement of thromboxane biosynthesis in health and disease. Front. Pharmacol. 2019;10:1244. doi: 10.3389/fphar.2019.01244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Eikelboom JW, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655. doi: 10.1161/01.CIR.0000013777.21160.07. [DOI] [PubMed] [Google Scholar]
- 9.Rade JJ, et al. Association of thromboxane generation with survival in aspirin users and nonusers. J. Am. Coll. Cardiol. 2022;80:233–250. doi: 10.1016/j.jacc.2022.04.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Joharatnam-Hogan N, et al. Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: A sub-study of the Add-Aspirin trial. Br. J. Cancer. 2023;129:706–720. doi: 10.1038/s41416-023-02310-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ito F, Sono Y, Ito T. Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress: Oxidative stress in diabetes, atherosclerosis, and chronic inflammation. Antioxidants. 2019;8:72. doi: 10.3390/antiox8030072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Awad JA, Morrow JD, Takahashi K, Roberts LJ., 2nd Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J. Biol. Chem. 1993;268:4161–4169. doi: 10.1016/S0021-9258(18)53593-6. [DOI] [PubMed] [Google Scholar]
- 13.Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem. Phys. Lipids. 2004;128:149–163. doi: 10.1016/j.chemphyslip.2003.10.001. [DOI] [PubMed] [Google Scholar]
- 14.Petrucci G, et al. Role of oxidative stress in the pathogenesis of atherothrombotic diseases. Antioxidants. 2022;11:1408. doi: 10.3390/antiox11071408. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Schwedhelm E, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: A matched case-control study. Circulation. 2004;109:843–848. doi: 10.1161/01.CIR.0000116761.93647.30. [DOI] [PubMed] [Google Scholar]
- 16.Roest M, et al. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J. Clin. Lipidol. 2008;2:298–303. doi: 10.1016/j.jacl.2008.06.004. [DOI] [PubMed] [Google Scholar]
- 17.Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl. J. Med. 2006;354:1706–1717. doi: 10.1056/NEJMoa060989. [DOI] [PubMed] [Google Scholar]
- 18.Wade LG. Organic Chemistry. Pearson Prentice Hall; 2006. [Google Scholar]
- 19.Petrucci G, et al. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. J. Thrombosis Haemostasis. 2019;17:885–895. doi: 10.1111/jth.14445. [DOI] [PubMed] [Google Scholar]
- 20.Zaccardi F, et al. In Vivo platelet activation and aspirin responsiveness in type 1 diabetes. Diabetes. 2015;65:503–509. doi: 10.2337/db15-0936. [DOI] [PubMed] [Google Scholar]
- 21.Santilli F, et al. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. Diabetes Metab. Res. Rev. 2020;36:e3232. doi: 10.1002/dmrr.3232. [DOI] [PubMed] [Google Scholar]
- 22.Petrucci G, et al. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation. Clin. Transl. Sci. 2022;15:2958–2970. doi: 10.1111/cts.13415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rocca B, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020;136:171–182. doi: 10.1182/blood.2019004596. [DOI] [PubMed] [Google Scholar]
- 24.Pagliaccia F, et al. Stability of urinary thromboxane A2 metabolites and adaptation of the extraction method to small urine volume. Clin. Lab. 2014;60:105–111. doi: 10.7754/Clin.Lab.2013.121238. [DOI] [PubMed] [Google Scholar]
- 25.Lellouche F, Fradin A, Fitzgerald G, Maclouf J. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins. 1990;40:297–310. doi: 10.1016/0090-6980(90)90017-P. [DOI] [PubMed] [Google Scholar]
- 26.Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: An alternative to radioimmunoassay. Anal. Chem. 1985;57:1170–1173. doi: 10.1021/ac00284a003. [DOI] [PubMed] [Google Scholar]
- 27.Wang Z, et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J. Pharmacol. Exp. Ther. 1995;275:94–100. [PubMed] [Google Scholar]
- 28.Murphy MP, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat. Metab. 2022;4:651–662. doi: 10.1038/s42255-022-00591-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Association WM. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053. [DOI] [PubMed] [Google Scholar]
- 30.Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J. Lipid Res. 2007;48:1607–1617. doi: 10.1194/jlr.M700097-JLR200. [DOI] [PubMed] [Google Scholar]
- 31.Holder C, et al. High-throughput and sensitive analysis of free and total 8-isoprostane in urine with isotope-dilution liquid chromatography-tandem mass spectrometry. ACS Omega. 2020;5:10919–10926. doi: 10.1021/acsomega.0c00661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sieminska J, et al. A single extraction 96-well method for LC-MS/MS quantification of urinary eicosanoids, steroids and drugs. Prostagland. Other Lipid Mediat. 2023;170:106789. doi: 10.1016/j.prostaglandins.2023.106789. [DOI] [PubMed] [Google Scholar]
- 33.Hobbs BA. Comparing models for measuring ring strain of common cycloalkanes. Corinthian. 2004;6:4. [Google Scholar]
- 34.Kanno T, et al. Literature review of the role of hydroxyl radicals in chemically-induced mutagenicity and carcinogenicity for the risk assessment of a disinfection system utilizing photolysis of hydrogen peroxide. J. Clin. Biochem. Nutr. 2012;51:9–14. doi: 10.3164/jcbn.11-105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Spierto FW, Hannon WH, Gunter EW, Smith SJ. Stability of urine creatinine1Use of trade names is for identification purposes only and does not constitute endorsement by the Public Health Service, or by the U.S. Department of Health and Human Services 1. Clin. Chim. Acta. 1997;264:227–232. doi: 10.1016/S0009-8981(97)00080-6. [DOI] [PubMed] [Google Scholar]
- 36.Fuller NJ, Elia M. Factors influencing the production of creatinine: Implications for the determination and interpretation of urinary creatinine and creatine in man. Clin. Chim. Acta. 1988;175:199–210. doi: 10.1016/0009-8981(88)90096-4. [DOI] [PubMed] [Google Scholar]
- 37.Remer T, Montenegro-Bethancourt G, Shi L. Long-term urine biobanking: Storage stability of clinical chemical parameters under moderate freezing conditions without use of preservatives. Clin. Biochem. 2014;47:307–311. doi: 10.1016/j.clinbiochem.2014.09.009. [DOI] [PubMed] [Google Scholar]
- 38.Stevens VL, Hoover E, Wang Y, Zanetti KA. Pre-analytical factors that affect metabolite stability in human urine, plasma, and serum: A review. Metabolites. 2019;9:156. doi: 10.3390/metabo9080156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Rotter M, et al. Stability of targeted metabolite profiles of urine samples under different storage conditions. Metabolomics. 2017;13:4. doi: 10.1007/s11306-016-1137-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Saude EJ, Sykes BD. Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics. 2007;3:19–27. doi: 10.1007/s11306-006-0042-2. [DOI] [Google Scholar]
- 41.Bao Y, Zuo L. Effect of repeated freeze-thaw cycles on urinary albumin-to-creatinine ratio. Scand. J. Clin. Lab. Investig. 2009;69:886–888. doi: 10.3109/00365510903323209. [DOI] [PubMed] [Google Scholar]
- 42.Zhang Y, et al. Effect of freeze/thaw cycles on several biomarkers in urine from patients with kidney disease. Biopreserv. Biobank. 2015;13:144–146. doi: 10.1089/bio.2014.0033. [DOI] [PubMed] [Google Scholar]
- 43.Gómez C, et al. Quantitative metabolic profiling of urinary eicosanoids for clinical phenotyping. J. Lipid Res. 2019;60:1164–1173. doi: 10.1194/jlr.D090571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Olson MT, et al. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. J. Thromb. Haemost. 2012;10:2462–2469. doi: 10.1111/jth.12026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Yan Z, Mas E, Mori TA, Croft KD, Barden AE. A significant proportion of F2-isoprostanes in human urine are excreted as glucuronide conjugates. Anal Biochem. 2010;403:126–128. doi: 10.1016/j.ab.2010.04.016. [DOI] [PubMed] [Google Scholar]
- 46.Cunningham TJ, et al. Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroinflammation. 2006;3:26. doi: 10.1186/1742-2094-3-26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Downey P, et al. Renal concentrating defect in mice lacking group IV cytosolic phospholipase A(2) Am. J. Physiol. Renal Physiol. 2001;280(4):F607–618. doi: 10.1152/ajprenal.2001.280.4.F607. [DOI] [PubMed] [Google Scholar]
- 48.Cunningham TJ, Yao L, Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J. Inflamm. 2008;5:17. doi: 10.1186/1476-9255-5-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Fabris C, et al. Urinary phospholipase A2 excretion in chronic pancreatic diseases. Int. J. Pancreatol. 1992;11:179–184. doi: 10.1007/BF02924183. [DOI] [PubMed] [Google Scholar]
- 50.Najafi A, et al. Supplementation of freezing and thawing media with brain-derived neurotrophic factor protects human sperm from freeze-thaw-induced damage. Fertil. Steril. 2016;106:1658–1665. doi: 10.1016/j.fertnstert.2016.09.004. [DOI] [PubMed] [Google Scholar]
- 51.Bahmyari R, Zare M, Sharma R, Agarwal A, Halvaei I. The efficacy of antioxidants in sperm parameters and production of reactive oxygen species levels during the freeze-thaw process: A systematic review and meta-analysis. Andrologia. 2020;52:e13514. doi: 10.1111/and.13514. [DOI] [PubMed] [Google Scholar]
- 52.Len JS, Koh WSD, Tan SX. The roles of reactive oxygen species and antioxidants in cryopreservation. Biosci. Rep. 2019;39:BSR20191601. doi: 10.1042/BSR20191601. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The dataset analyzed in the current study can be acquired from the corresponding author upon motivated request.




